To test efficacy and safety of atorvastatin in subjects with clinically isolated syndrome (CIS).
binding proteins that activate molecules involved in T-cell differentiation. 2, 4 These findings suggested statins may be beneficial in treatment of MS.
In one crossover MS study, simvastatin decreased the number of new T2 hyperintense lesions on brain MRI scans compared to pretherapy. 5 MS studies subsequently tested statins in combination with interferon-␤ (IFN␤). 6 -10 Whether a statin medication alone is beneficial has never been tested in a placebocontrolled trial. We hypothesized that the potential anti-inflammatory effects of statins would be beneficial in the earliest phase of clinical MS. When this study was designed, one published trial had shown benefit of IFN␤-1a in clinically isolated syndromes (CIS). 11 The objective of the STAyCIS study was to test the effi-cacy and safety of atorvastatin (Lipitor, Pfizer, New York, NY) 80 mg daily vs placebo in subjects with CIS. Our primary endpoint (PEP) was the proportion of subjects who developed 3 or more new brain MRI T2 lesions or a clinical relapse within 12 months. Secondary endpoints included proportion of subjects who remained free of new brain MRI T2 lesions, cumulative number of new brain MRI T2 lesions, and proportion of subjects who remained free of new gadolinium-enhancing (Gd) lesions.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by institutional review boards at 14 centers in the United States and Canada. Written informed consent was obtained from subjects prior to enrollment in the STAyCIS study (NCT00094172).
Study design.
STAyCIS is a 12-month phase II, randomized, multicenter, controlled double-blind trial of atorvastatin 80 mg once daily vs placebo. The PEP was chosen based upon data from the CHAMPS study. 11 It was determined that a 26% treatment effect would have been found at 12 months with a composite outcome of Ն3 new brain MRI lesions or Ն1 MS relapse, and that 69% of the placebo group would have met that endpoint by 12 months. This outcome was chosen for the PEP as in clinical practice it would likely have led to initiation of an approved DMT. With the assumption that 69% of placebo subjects would meet the PEP by month 12, we determined that 152 subjects would be required using a 3:2 randomization (atorvastatin: placebo) to detect a 39% therapeutic effect, with a power of 0.80 at a significance level (2-tailed) of 0.05, assuming a 10% dropout rate. Subjects who met the PEP were offered IFN␤-1a 30 g IM weekly initiated after their month 6 visit and remained in the study until month 12. Secondary endpoints included incidence of adverse events, proportion of subjects free of new T2 and Gd lesions up to month 12 or to IFN␤-1a initiation, cumulative number of T2 and Gd lesions to month 12 or to IFN␤-1a initiation, time to first relapse, changes in Expanded Disability Status Scale (EDSS), 12 Multiple Sclerosis Functional Composite (MSFC), 13 visual analog scale (VAS) of well-being, and T1 and T2 lesion volumes.
Brain MRI scans and VAS were obtained at baseline, months 3, 6, 9, and 12. Clinical (EDSS, physical, MSFC) and laboratory evaluations occurred at screening, baseline, months 1, 2, 3, 6, 9, and 12. All subjects were required to complete a 3-day course of IV methylprednisolone 1 g daily or equivalent, started within 90 days of CIS onset. Steroids were discontinued Ն28 days before any MRI scan. Subjects experiencing new symptoms suggestive of an MS relapse were examined within 7 days. Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, persisting Ͼ48 hours in subjects who were neurologically stable or improving for at least 30 days following CIS. Relapses were confirmed only when symptoms were accompanied by new objective changes on clinical examination. Recurrent neurologic symptoms of the same nature and severity as the prior one or change in sphincter or cognitive function alone did not qualify as relapses. Subjects started on atorvastatin 80 mg once daily or placebo at baseline. 14 Subjects exhibiting aspartate aminotransferase or alanine aminotransferase elevation (Ͼ3ϫ normal upper limit [NUL] but Ͻ10ϫ NUL) on 2 consecutive draws decreased study medication to 40 mg. Subjects who experienced low low-density lipoprotein cholesterol levels (Ͻ25 mg/dL) discontinued medication for 1 month. If upon retesting levels were Ն25 mg/dL but Յ30 mg/dL study drug was restarted at 40 mg. Subjects returned for follow-up visits at months 15 and 18. Patients who did not meet the PEP during the 12-month treatment phase and developed no new MRI lesions after month 3 received brain MRI scans at months 15 and 18 to address whether there could be sustained effects after atorvastatin discontinuation ("exploratory tolerance phase").
Inclusion criteria. Subjects between 18 and 55 years with a CIS lasting Ն48 hours, seen within 90 days of symptom onset, were offered participation provided they had Ն2 silent MRI T2hyperintense foci Ն3 mm in diameter (2 brain or 1 brain and 1 spinal cord). Subjects were naive to approved and off-label MS DMT. They could not have received cholesterol-lowering agents for 3 months prior to screening, and must have had normal hepatic function.
Randomization. The randomization sequence was computergenerated in balanced block sizes of 5, stratified by center. Study drug kits were provided to the site pharmacist labeled with site and subject number. The study coordinator contacted the pharmacist to receive the subject number and corresponding study drug. The masked statistician and drug distributor maintained the randomization list containing treatment groups. Site staff were masked to treatment assignment.
MRI scanning and analysis. Brain MRI (whole brain T2/ T1-weighted images yielding 1 ϫ 1 ϫ 3 mm 3 resolution without gap) with injection of single-dose Gd was acquired according to a standardized protocol at each site on a 1.5-T magnet. A central MRI reading unit (UCSF, San Francisco) evaluated MRI scans for quality and measurement of study endpoints without knowledge of treatment assignments.
T2 lesion volume analysis was performed on all scans using a semiautomated thresholding method and manual editing with simultaneous view access to T2 and PD-weighted slices. An automated coregistration procedure was applied on subsequent timepoints onto each subject baseline scan.
Volumetric high-resolution (1 mm 3 , 124 slices) T1weighted gradient-echo images were used to measure annual percent brain volume changes derived from SIENA, 15 and normalized gray and white matter volumes generated by SIENAX (Image Analysis Group, Oxford, UK). T1-lesion masks were incorporated into the SIENAX program to correct for misclassifications of parenchymal tissue.
Statistical analyses. The primary analysis tested equality of survival distributions between the 2 groups using a log-rank test. Subjects were censored at initiation of IFN␤-1a if they started prior to meeting the endpoint. Secondary analyses were performed using Fisher exact test. For secondary analyses, subjects terminating the study before month 12 due to voluntary withdrawal were considered to not have met PEP.
Subjects who began IFN␤-1a before month 12 were excluded from change-from-baseline secondary endpoints. For secondary time-to-event endpoints, subjects were censored at initiation of IFN␤-1a if they did not experience the event. Count data were truncated at the IFN␤-1a start date if subjects started IFN␤-1a before month 12. During the first 12 months of treatment, IFN␤-1a has no proven effect on atrophy measures 16 ; therefore month 12 atrophy measures were included for all subjects with data, regardless of whether they initiated IFN␤-1a. Secondary endpoint analysis methods included Fisher exact tests for proportions, log-rank tests for time-to-event data, Wilcoxon rank sum test or t tests for continuous data, and zeroinflated Poisson models. For analysis of T2 and Gd lesions, the model was adjusted for baseline lesion count and time to starting IFN␤-1a. The model for rate of lesions per month after starting IFN␤-1a was adjusted for baseline lesion counts and age.
All analyses were performed on the intent-to-treat sample, which included all randomized subjects who received any study drug. No data for secondary endpoints were imputed. Thirty-six subjects (20 in the atorvastatin group and 16 in the placebo group) received IFN␤-1a. Mean duration subjects were on IFN␤-1a was 151.3 Ϯ 62.1 days for the atorvastatin group and 143.2 Ϯ 76.9 days for the placebo group.
RESULTS

Imaging secondary endpoints. Proportion of lesion-free
subjects. The proportion of subjects who did not develop new T2 lesions to month 12 or to starting IFN␤-1a was 55.3% in the atorvastatin and 27.6% in the placebo group ( p ϭ 0.03) (table 2, figure 2 ), which represents a 50% relative reduction favoring atorvastatin treatment. Odds of remaining T2-free was higher in the atorvastatin group compared with placebo: odds ratio (OR) ϭ 4.34 (p ϭ 0.01). For subjects who exhibited new T2 lesions, there was no difference between groups (p ϭ 0.73). The odds of remaining Gd-free tended to be higher in the atorvastatin group compared with placebo: OR ϭ 2.72 (p ϭ 0.11). For subjects who exhibited new Gd lesions, there was no difference between groups (p ϭ 0.65).
Median cumulative number of new T2 and gadoliniumenhanced lesions.
Median cumulative numbers of new T2 lesions to month 12 or to starting IFN␤-1a were 0 (range 0 -17, mean 2.2 Ϯ 3.6) and 2 (range 0 -15, mean 3.0 Ϯ 3.3) in atorvastatin and placebo groups. This corresponds to a 27% reduction in the mean cumulative number of T2 lesions ( p ϭ 0.08). Median cumulative numbers of Gd lesions to month 12 or before starting IFN␤-1a were 0 in both groups (atorvastatin range 0 -12, mean 1.1 Ϯ 2.3; placebo range 0 -8, mean 1.2 Ϯ 2.0). 
Changes in T1 or T2 lesion volume from baseline to month 12. No difference between groups was seen for changes in T1 and T2 lesion volumes between baseline and month 12 for subjects not initiating
Effect of the combination of atorvastatin and IFN␤-1a
on MRI activity. No clear antagonistic effect of combination of atorvastatin and IFN␤-1a compared to placebo and IFN␤-1a was found on the number of new T2 and Gd lesions (table e-2).
Safety.
A total of 961 treatment-emergent (TE) adverse events (AEs) were reported (table 3) . The majority (82.7%) of subjects had AEs that were judged grade 1 (mild) or grade 2 (moderate) in severity.
A total of 213 TE AEs occurred after IFN␤-1a was started for subjects meeting the PEP, including 125 in the atorvastatin group and 88 in the placebo group. The 5 most common TE AEs experienced were disease progression (51.9%), hypoesthesia (43.2%), paraesthesia (25.9%), fatigue (24.7%), and headache (23.5%). Disease progression and hypoesthesia were reported in a greater percentage of subjects in the placebo group (59.4% and 50.0%) than the atorvastatin group (46.9% and 38.8%). Paraesthesia, fatigue, and headache were reported nearly equally across groups (atorvastatin: 26.5%, 26.5%, and 24.5%; placebo: 25.0%, 21.9%, and 21.9%). The following AEs occurred more frequently in subjects who received IFN␤-1a in combination with atorvastatin than placebo: headache (27.8% vs 6.7%), elevation of alanine aminotransferase (27.8% vs 0%) or aspartate aminotransferase (27.8% vs 0%), and nausea (16.7% vs 0%).
Blinding analysis. When EDSS physicians were asked the treatment assignment for atorvastatin-treated subjects, 33 (89.2%) responded "do not know," 2 (5.4%) guessed correctly, and 2 (5.4%) incorrectly. For placebo subjects, 24 (88.9%) EDSS physicians responded "do not know," 2 (7.4%) guessed correctly, and 1 (3.7%) incorrectly. When treating physicians were asked the treatment assignment for atorvastatin-treated subjects, 23 (59%) responded "do not know," 14 (35.9%) guessed correctly, and 2 (5.1%) incorrectly. For placebo subjects, 20 (69%) treating physicians responded "do not know," 7 (24.1%) guessed correctly, and 2 (6.9%) incorrectly. When atorvastatin-treated subjects were asked to guess their treatment assignment, 8 (20.5%) responded "do not know," 23 (59%) guessed correctly, and 8 (20.5%) incorrectly. When placebo subjects were asked to guess their treatment assignment, 9 (31%) responded "do not know," 14 (48.3%) guessed correctly, and 6 (20.7%) incorrectly. Exploratory tolerance phase. Twenty-six patients (18 atorvastatin, 8 placebo) who did not meet the PEP and developed no new MRI lesions after month 3 entered a "tolerance phase" to determine whether there could be sustained clinical and imaging effects in the 6 months after discontinuation of atorvastatin. These subjects received brain MRIs at month 15 and 18. Ten atorvastatin subjects (55.6%), but none of the placebo subjects, developed new MRI lesions or experienced an exacerbation during those 6 months (p ϭ 0.03), findings that did not support a tolerogenic effect of atorvastatin. DISCUSSION We report the only randomized double-blind controlled phase II trial that has tested whether a statin alone can reduce MS activity against placebo. The PEP was not met. However, secondary imaging endpoints were positive, suggesting a beneficial effect of atorvastatin compared with placebo. In this regard, there was a significant reduction in the Proportion of subjects with cumulative T2 lesion counts up to 12 months or prior to starting interferon ␤-1a (IFN␤-1a)
Data represent the proportion of subjects (y-axis) and the cumulative T2 lesion counts (x-axis) up to 12 months or prior to starting IFN␤-1a according to treatment group (blue ϭ atorvastatin, red ϭ placebo). Fifty-five percent of subjects receiving atorvastatin compared to 27% of subjects receiving placebo (p ϭ 0.03) remained free of new T2 hyperintense lesions during the study period.
risk to develop new T2 hyperintense foci in the atorvastatin group to month 12 or to initiation of IFN␤-1a (OR ϭ 4.34; table 2). This was observed despite early discontinuation of enrollment and some randomization imbalance, namely higher T1 disease burden in the atorvastatin group (table 1) . In addition, the exploratory tolerance phase suggested a higher disease activity in stable patients after discontinuing atorvastatin vs placebo (p ϭ 0.03).
Other investigations have examined the role of various statins as MS therapy. [5] [6] [7] [8] [9] [10] Our imaging findings in CIS are comparable to those reported in the only other trial that tested statin monotherapy in MS. In that earlier study, 30 patients with relapsingremitting MS were treated with simvastatin in an open-label single crossover design. Simvastatin treatment was associated with a 30% reduction in number of new T2 hyperintense foci, suggesting a beneficial effect. 5 That design, however, was subject to regression to the mean, 17 a concern averted in a placebo-controlled trial.
Our study has limitations. Beside underenrollment, the placebo group exhibited less clinical and radiologic activity than subjects included in the CHAMPS dataset used for our power calculation. 11 Further, the composite PEP had never been tested as an endpoint in previous MS trials. Its sensitivity to detect changes in disease activity and treatment effects will require further clarification. As is typical for MS trials, this study was relatively short (1 year), which may limit the generalizability of our findings. In addition, the number of subjects who reduced study medication dosage due to unwanted clinical or laboratory-documented side effects was greater than anticipated, and may have decreased our ability to detect clinical effects.
For ethical reasons, subjects were offered to start on an approved DMT if they exhibited clinical or MRI activity (i.e., after meeting the PEP) so that all subjects contributed to the primary analysis. Such a study design impacts analyses of secondary endpoints not based on time to meet PEP, as data acquired at later time points could be confounded by concomitant IFN␤-1a. Therefore, our secondary analyses, except for atrophy measures, only used endpoints collected to month 12 for those subjects who did not start on DMT, and to initiation of IFN␤-1a for subjects who met the PEP before month 12.
As statins have a different mechanism of action than approved MS medications, they may have added benefit when used in combination. 18 Statins have been tested in subjects with MS in combination with IFN␤. Two studies have suggested that the addition of oral statin to IFN␤ therapy may result in a paradoxical increase in MS activity compared to subjects receiving IFN␤-1a alone. 6, 10 One theoretical possibility for such potential antagonism may relate to the opposing activity of type I interferon on STAT1 phosphorylation, 19 i.e., statins inhibit STAT1 phosphorylation, 19 -21 whereas activation of the type I IFN receptor induces STAT1 phosphorylation. 22 However, not all MS clinical studies have detected antagonism of IFN␤ therapy by statins. 8, 9, 23 We did not observe that addition of weekly IM IFN␤-1a 30 g to atorvastatin in the rescue phase significantly reduced the treatment effect of IFN␤-1a on new T2 or Gd lesions. The degree of antagonism may be related to individual doses of these medications. Our study may also have been too small or the rescue phase too short to rule out such an effect. Given the concern for antagonism between a statin and IFN␤, one should be cautious in judging the potential benefit provided by a statin in MS therapy, based upon trials that have only tested a statin in combination with IFN␤.
Atorvastatin did not impact the clinical endpoint in this trial. However, as positive MRI results were observed, future studies to confirm the effect of statins in MS are warranted. Such studies may require enrolling greater numbers of subjects to provide sufficient power to assess the influence on clinical measures.
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